Loading…

Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes

Natural killer (NK) cells are non-antigen specific innate immune cells that can be redirected to targets of interest using multiple strategies, although none are currently FDA-approved. We sought to evaluate NK cell infiltration into tumors to develop an improved understanding of which histologies m...

Full description

Saved in:
Bibliographic Details
Published in:Prostate cancer and prostatic diseases 2024-02
Main Authors: Zorko, Nicholas A, Makovec, Allison, Elliott, Andrew, Kellen, Samuel, Lozada, John R, Arafa, Ali T, Felices, Martin, Shackelford, Madison, Barata, Pedro, Zakharia, Yousef, Narayan, Vivek, Stein, Mark N, Zarrabi, Kevin K, Patniak, Akash, Bilen, Mehmet A, Radovich, Milan, Sledge, George, El-Deiry, Wafik S, Heath, Elisabeth I, Hoon, Dave S B, Nabhan, Chadi, Miller, Jeffrey S, Hwang, Justin H, Antonarakis, Emmanuel S
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c298t-98b7240abd7bcbc9ae15516dc137f7289c44e1f81e327b1c588c869e3c9429733
container_end_page
container_issue
container_start_page
container_title Prostate cancer and prostatic diseases
container_volume
creator Zorko, Nicholas A
Makovec, Allison
Elliott, Andrew
Kellen, Samuel
Lozada, John R
Arafa, Ali T
Felices, Martin
Shackelford, Madison
Barata, Pedro
Zakharia, Yousef
Narayan, Vivek
Stein, Mark N
Zarrabi, Kevin K
Patniak, Akash
Bilen, Mehmet A
Radovich, Milan
Sledge, George
El-Deiry, Wafik S
Heath, Elisabeth I
Hoon, Dave S B
Nabhan, Chadi
Miller, Jeffrey S
Hwang, Justin H
Antonarakis, Emmanuel S
description Natural killer (NK) cells are non-antigen specific innate immune cells that can be redirected to targets of interest using multiple strategies, although none are currently FDA-approved. We sought to evaluate NK cell infiltration into tumors to develop an improved understanding of which histologies may be most amenable to NK cell-based therapies currently in the developmental pipeline. DNA (targeted/whole-exome) and RNA (whole-transcriptome) sequencing was performed from tumors from 45 cancer types (N = 90,916 for all cancers and N = 3365 for prostate cancer) submitted to Caris Life Sciences. NK cell fractions and immune deconvolution were inferred from RNA-seq data using quanTIseq. Real-world overall survival (OS) and treatment status was determined and Kaplan-Meier estimates were calculated. Statistical significance was determined using X and Mann-Whitney U tests, with corrections for multiple comparisons where appropriate. In both a pan-tumor and prostate cancer (PCa) -specific setting, we demonstrated that NK cells represent a substantial proportion of the total cellular infiltrate (median range 2-9% for all tumors). Higher NK cell infiltration was associated with improved OS in 28 of 45 cancer types, including (PCa). NK cell infiltration was negatively correlated with common driver mutations and androgen receptor variants (AR-V7) in primary prostate biopsies, while positively correlated with negative immune regulators. Higher levels of NK cell infiltration were associated with patterns consistent with a compensatory anti-inflammatory response. Using the largest available dataset to date, we demonstrated that NK cells infiltrate a broad range of tumors, including both primary and metastatic PCa. NK cell infiltration is associated with improved PCa patient outcomes. This study demonstrates that NK cells are capable of trafficking to both primary and metastatic PCa and are a viable option for immunotherapy approaches moving forward. Future development of strategies to enhance tumor-infiltrating NK cell-mediated cytolytic activity and activation while limiting inhibitory pathways will be key.
doi_str_mv 10.1038/s41391-024-00797-0
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2933462676</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2933462676</sourcerecordid><originalsourceid>FETCH-LOGICAL-c298t-98b7240abd7bcbc9ae15516dc137f7289c44e1f81e327b1c588c869e3c9429733</originalsourceid><addsrcrecordid>eNo9kElPwzAQhS0EoqXwBzggH7kEvMXLEVUsFRXtAbhajjORgrIU20Hi32MocJrR6L2neR9C55RcUcL1dRSUG1oQJgpClFEFOUBzKpQsSkn0Yd65LAulSzZDJzG-EUIMNeQYzbgWVGvD5uj1yaUpuA4_tl0HAS-h6_BqaNouBZfaccDtgLdhjMklwEs3eAgxH6BufcKrfhfGD6jxNmthSHgzJT_2EE_RUeO6CGe_c4Fe7m6flw_FenO_Wt6sC8-MToXRlWKCuKpWla-8cUDLksraU64axbTxQgBtNAXOVEV9qbXX0gD3RjCjOF-gy31u_uN9gphs30afO7gBxilaZjgXkkkls5TtpT63iQEauwtt78KnpcR-87R7njbztD88Lcmmi9_8qeqh_rf8AeRf3u5wmw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2933462676</pqid></control><display><type>article</type><title>Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes</title><source>Springer Nature</source><creator>Zorko, Nicholas A ; Makovec, Allison ; Elliott, Andrew ; Kellen, Samuel ; Lozada, John R ; Arafa, Ali T ; Felices, Martin ; Shackelford, Madison ; Barata, Pedro ; Zakharia, Yousef ; Narayan, Vivek ; Stein, Mark N ; Zarrabi, Kevin K ; Patniak, Akash ; Bilen, Mehmet A ; Radovich, Milan ; Sledge, George ; El-Deiry, Wafik S ; Heath, Elisabeth I ; Hoon, Dave S B ; Nabhan, Chadi ; Miller, Jeffrey S ; Hwang, Justin H ; Antonarakis, Emmanuel S</creator><creatorcontrib>Zorko, Nicholas A ; Makovec, Allison ; Elliott, Andrew ; Kellen, Samuel ; Lozada, John R ; Arafa, Ali T ; Felices, Martin ; Shackelford, Madison ; Barata, Pedro ; Zakharia, Yousef ; Narayan, Vivek ; Stein, Mark N ; Zarrabi, Kevin K ; Patniak, Akash ; Bilen, Mehmet A ; Radovich, Milan ; Sledge, George ; El-Deiry, Wafik S ; Heath, Elisabeth I ; Hoon, Dave S B ; Nabhan, Chadi ; Miller, Jeffrey S ; Hwang, Justin H ; Antonarakis, Emmanuel S</creatorcontrib><description>Natural killer (NK) cells are non-antigen specific innate immune cells that can be redirected to targets of interest using multiple strategies, although none are currently FDA-approved. We sought to evaluate NK cell infiltration into tumors to develop an improved understanding of which histologies may be most amenable to NK cell-based therapies currently in the developmental pipeline. DNA (targeted/whole-exome) and RNA (whole-transcriptome) sequencing was performed from tumors from 45 cancer types (N = 90,916 for all cancers and N = 3365 for prostate cancer) submitted to Caris Life Sciences. NK cell fractions and immune deconvolution were inferred from RNA-seq data using quanTIseq. Real-world overall survival (OS) and treatment status was determined and Kaplan-Meier estimates were calculated. Statistical significance was determined using X and Mann-Whitney U tests, with corrections for multiple comparisons where appropriate. In both a pan-tumor and prostate cancer (PCa) -specific setting, we demonstrated that NK cells represent a substantial proportion of the total cellular infiltrate (median range 2-9% for all tumors). Higher NK cell infiltration was associated with improved OS in 28 of 45 cancer types, including (PCa). NK cell infiltration was negatively correlated with common driver mutations and androgen receptor variants (AR-V7) in primary prostate biopsies, while positively correlated with negative immune regulators. Higher levels of NK cell infiltration were associated with patterns consistent with a compensatory anti-inflammatory response. Using the largest available dataset to date, we demonstrated that NK cells infiltrate a broad range of tumors, including both primary and metastatic PCa. NK cell infiltration is associated with improved PCa patient outcomes. This study demonstrates that NK cells are capable of trafficking to both primary and metastatic PCa and are a viable option for immunotherapy approaches moving forward. Future development of strategies to enhance tumor-infiltrating NK cell-mediated cytolytic activity and activation while limiting inhibitory pathways will be key.</description><identifier>ISSN: 1365-7852</identifier><identifier>ISSN: 1476-5608</identifier><identifier>EISSN: 1476-5608</identifier><identifier>DOI: 10.1038/s41391-024-00797-0</identifier><identifier>PMID: 38418892</identifier><language>eng</language><publisher>England</publisher><ispartof>Prostate cancer and prostatic diseases, 2024-02</ispartof><rights>2024. The Author(s).</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c298t-98b7240abd7bcbc9ae15516dc137f7289c44e1f81e327b1c588c869e3c9429733</cites><orcidid>0000-0001-7021-968X ; 0000-0003-1381-2713 ; 0009-0008-2487-9079 ; 0000-0002-8205-738X ; 0000-0003-0031-9655 ; 0000-0001-9480-2626</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38418892$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zorko, Nicholas A</creatorcontrib><creatorcontrib>Makovec, Allison</creatorcontrib><creatorcontrib>Elliott, Andrew</creatorcontrib><creatorcontrib>Kellen, Samuel</creatorcontrib><creatorcontrib>Lozada, John R</creatorcontrib><creatorcontrib>Arafa, Ali T</creatorcontrib><creatorcontrib>Felices, Martin</creatorcontrib><creatorcontrib>Shackelford, Madison</creatorcontrib><creatorcontrib>Barata, Pedro</creatorcontrib><creatorcontrib>Zakharia, Yousef</creatorcontrib><creatorcontrib>Narayan, Vivek</creatorcontrib><creatorcontrib>Stein, Mark N</creatorcontrib><creatorcontrib>Zarrabi, Kevin K</creatorcontrib><creatorcontrib>Patniak, Akash</creatorcontrib><creatorcontrib>Bilen, Mehmet A</creatorcontrib><creatorcontrib>Radovich, Milan</creatorcontrib><creatorcontrib>Sledge, George</creatorcontrib><creatorcontrib>El-Deiry, Wafik S</creatorcontrib><creatorcontrib>Heath, Elisabeth I</creatorcontrib><creatorcontrib>Hoon, Dave S B</creatorcontrib><creatorcontrib>Nabhan, Chadi</creatorcontrib><creatorcontrib>Miller, Jeffrey S</creatorcontrib><creatorcontrib>Hwang, Justin H</creatorcontrib><creatorcontrib>Antonarakis, Emmanuel S</creatorcontrib><title>Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes</title><title>Prostate cancer and prostatic diseases</title><addtitle>Prostate Cancer Prostatic Dis</addtitle><description>Natural killer (NK) cells are non-antigen specific innate immune cells that can be redirected to targets of interest using multiple strategies, although none are currently FDA-approved. We sought to evaluate NK cell infiltration into tumors to develop an improved understanding of which histologies may be most amenable to NK cell-based therapies currently in the developmental pipeline. DNA (targeted/whole-exome) and RNA (whole-transcriptome) sequencing was performed from tumors from 45 cancer types (N = 90,916 for all cancers and N = 3365 for prostate cancer) submitted to Caris Life Sciences. NK cell fractions and immune deconvolution were inferred from RNA-seq data using quanTIseq. Real-world overall survival (OS) and treatment status was determined and Kaplan-Meier estimates were calculated. Statistical significance was determined using X and Mann-Whitney U tests, with corrections for multiple comparisons where appropriate. In both a pan-tumor and prostate cancer (PCa) -specific setting, we demonstrated that NK cells represent a substantial proportion of the total cellular infiltrate (median range 2-9% for all tumors). Higher NK cell infiltration was associated with improved OS in 28 of 45 cancer types, including (PCa). NK cell infiltration was negatively correlated with common driver mutations and androgen receptor variants (AR-V7) in primary prostate biopsies, while positively correlated with negative immune regulators. Higher levels of NK cell infiltration were associated with patterns consistent with a compensatory anti-inflammatory response. Using the largest available dataset to date, we demonstrated that NK cells infiltrate a broad range of tumors, including both primary and metastatic PCa. NK cell infiltration is associated with improved PCa patient outcomes. This study demonstrates that NK cells are capable of trafficking to both primary and metastatic PCa and are a viable option for immunotherapy approaches moving forward. Future development of strategies to enhance tumor-infiltrating NK cell-mediated cytolytic activity and activation while limiting inhibitory pathways will be key.</description><issn>1365-7852</issn><issn>1476-5608</issn><issn>1476-5608</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kElPwzAQhS0EoqXwBzggH7kEvMXLEVUsFRXtAbhajjORgrIU20Hi32MocJrR6L2neR9C55RcUcL1dRSUG1oQJgpClFEFOUBzKpQsSkn0Yd65LAulSzZDJzG-EUIMNeQYzbgWVGvD5uj1yaUpuA4_tl0HAS-h6_BqaNouBZfaccDtgLdhjMklwEs3eAgxH6BufcKrfhfGD6jxNmthSHgzJT_2EE_RUeO6CGe_c4Fe7m6flw_FenO_Wt6sC8-MToXRlWKCuKpWla-8cUDLksraU64axbTxQgBtNAXOVEV9qbXX0gD3RjCjOF-gy31u_uN9gphs30afO7gBxilaZjgXkkkls5TtpT63iQEauwtt78KnpcR-87R7njbztD88Lcmmi9_8qeqh_rf8AeRf3u5wmw</recordid><startdate>20240228</startdate><enddate>20240228</enddate><creator>Zorko, Nicholas A</creator><creator>Makovec, Allison</creator><creator>Elliott, Andrew</creator><creator>Kellen, Samuel</creator><creator>Lozada, John R</creator><creator>Arafa, Ali T</creator><creator>Felices, Martin</creator><creator>Shackelford, Madison</creator><creator>Barata, Pedro</creator><creator>Zakharia, Yousef</creator><creator>Narayan, Vivek</creator><creator>Stein, Mark N</creator><creator>Zarrabi, Kevin K</creator><creator>Patniak, Akash</creator><creator>Bilen, Mehmet A</creator><creator>Radovich, Milan</creator><creator>Sledge, George</creator><creator>El-Deiry, Wafik S</creator><creator>Heath, Elisabeth I</creator><creator>Hoon, Dave S B</creator><creator>Nabhan, Chadi</creator><creator>Miller, Jeffrey S</creator><creator>Hwang, Justin H</creator><creator>Antonarakis, Emmanuel S</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7021-968X</orcidid><orcidid>https://orcid.org/0000-0003-1381-2713</orcidid><orcidid>https://orcid.org/0009-0008-2487-9079</orcidid><orcidid>https://orcid.org/0000-0002-8205-738X</orcidid><orcidid>https://orcid.org/0000-0003-0031-9655</orcidid><orcidid>https://orcid.org/0000-0001-9480-2626</orcidid></search><sort><creationdate>20240228</creationdate><title>Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes</title><author>Zorko, Nicholas A ; Makovec, Allison ; Elliott, Andrew ; Kellen, Samuel ; Lozada, John R ; Arafa, Ali T ; Felices, Martin ; Shackelford, Madison ; Barata, Pedro ; Zakharia, Yousef ; Narayan, Vivek ; Stein, Mark N ; Zarrabi, Kevin K ; Patniak, Akash ; Bilen, Mehmet A ; Radovich, Milan ; Sledge, George ; El-Deiry, Wafik S ; Heath, Elisabeth I ; Hoon, Dave S B ; Nabhan, Chadi ; Miller, Jeffrey S ; Hwang, Justin H ; Antonarakis, Emmanuel S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c298t-98b7240abd7bcbc9ae15516dc137f7289c44e1f81e327b1c588c869e3c9429733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zorko, Nicholas A</creatorcontrib><creatorcontrib>Makovec, Allison</creatorcontrib><creatorcontrib>Elliott, Andrew</creatorcontrib><creatorcontrib>Kellen, Samuel</creatorcontrib><creatorcontrib>Lozada, John R</creatorcontrib><creatorcontrib>Arafa, Ali T</creatorcontrib><creatorcontrib>Felices, Martin</creatorcontrib><creatorcontrib>Shackelford, Madison</creatorcontrib><creatorcontrib>Barata, Pedro</creatorcontrib><creatorcontrib>Zakharia, Yousef</creatorcontrib><creatorcontrib>Narayan, Vivek</creatorcontrib><creatorcontrib>Stein, Mark N</creatorcontrib><creatorcontrib>Zarrabi, Kevin K</creatorcontrib><creatorcontrib>Patniak, Akash</creatorcontrib><creatorcontrib>Bilen, Mehmet A</creatorcontrib><creatorcontrib>Radovich, Milan</creatorcontrib><creatorcontrib>Sledge, George</creatorcontrib><creatorcontrib>El-Deiry, Wafik S</creatorcontrib><creatorcontrib>Heath, Elisabeth I</creatorcontrib><creatorcontrib>Hoon, Dave S B</creatorcontrib><creatorcontrib>Nabhan, Chadi</creatorcontrib><creatorcontrib>Miller, Jeffrey S</creatorcontrib><creatorcontrib>Hwang, Justin H</creatorcontrib><creatorcontrib>Antonarakis, Emmanuel S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Prostate cancer and prostatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zorko, Nicholas A</au><au>Makovec, Allison</au><au>Elliott, Andrew</au><au>Kellen, Samuel</au><au>Lozada, John R</au><au>Arafa, Ali T</au><au>Felices, Martin</au><au>Shackelford, Madison</au><au>Barata, Pedro</au><au>Zakharia, Yousef</au><au>Narayan, Vivek</au><au>Stein, Mark N</au><au>Zarrabi, Kevin K</au><au>Patniak, Akash</au><au>Bilen, Mehmet A</au><au>Radovich, Milan</au><au>Sledge, George</au><au>El-Deiry, Wafik S</au><au>Heath, Elisabeth I</au><au>Hoon, Dave S B</au><au>Nabhan, Chadi</au><au>Miller, Jeffrey S</au><au>Hwang, Justin H</au><au>Antonarakis, Emmanuel S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes</atitle><jtitle>Prostate cancer and prostatic diseases</jtitle><addtitle>Prostate Cancer Prostatic Dis</addtitle><date>2024-02-28</date><risdate>2024</risdate><issn>1365-7852</issn><issn>1476-5608</issn><eissn>1476-5608</eissn><abstract>Natural killer (NK) cells are non-antigen specific innate immune cells that can be redirected to targets of interest using multiple strategies, although none are currently FDA-approved. We sought to evaluate NK cell infiltration into tumors to develop an improved understanding of which histologies may be most amenable to NK cell-based therapies currently in the developmental pipeline. DNA (targeted/whole-exome) and RNA (whole-transcriptome) sequencing was performed from tumors from 45 cancer types (N = 90,916 for all cancers and N = 3365 for prostate cancer) submitted to Caris Life Sciences. NK cell fractions and immune deconvolution were inferred from RNA-seq data using quanTIseq. Real-world overall survival (OS) and treatment status was determined and Kaplan-Meier estimates were calculated. Statistical significance was determined using X and Mann-Whitney U tests, with corrections for multiple comparisons where appropriate. In both a pan-tumor and prostate cancer (PCa) -specific setting, we demonstrated that NK cells represent a substantial proportion of the total cellular infiltrate (median range 2-9% for all tumors). Higher NK cell infiltration was associated with improved OS in 28 of 45 cancer types, including (PCa). NK cell infiltration was negatively correlated with common driver mutations and androgen receptor variants (AR-V7) in primary prostate biopsies, while positively correlated with negative immune regulators. Higher levels of NK cell infiltration were associated with patterns consistent with a compensatory anti-inflammatory response. Using the largest available dataset to date, we demonstrated that NK cells infiltrate a broad range of tumors, including both primary and metastatic PCa. NK cell infiltration is associated with improved PCa patient outcomes. This study demonstrates that NK cells are capable of trafficking to both primary and metastatic PCa and are a viable option for immunotherapy approaches moving forward. Future development of strategies to enhance tumor-infiltrating NK cell-mediated cytolytic activity and activation while limiting inhibitory pathways will be key.</abstract><cop>England</cop><pmid>38418892</pmid><doi>10.1038/s41391-024-00797-0</doi><orcidid>https://orcid.org/0000-0001-7021-968X</orcidid><orcidid>https://orcid.org/0000-0003-1381-2713</orcidid><orcidid>https://orcid.org/0009-0008-2487-9079</orcidid><orcidid>https://orcid.org/0000-0002-8205-738X</orcidid><orcidid>https://orcid.org/0000-0003-0031-9655</orcidid><orcidid>https://orcid.org/0000-0001-9480-2626</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1365-7852
ispartof Prostate cancer and prostatic diseases, 2024-02
issn 1365-7852
1476-5608
1476-5608
language eng
recordid cdi_proquest_miscellaneous_2933462676
source Springer Nature
title Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T03%3A38%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Natural%20Killer%20Cell%20Infiltration%20in%20Prostate%20Cancers%20Predict%20Improved%20Patient%20Outcomes&rft.jtitle=Prostate%20cancer%20and%20prostatic%20diseases&rft.au=Zorko,%20Nicholas%20A&rft.date=2024-02-28&rft.issn=1365-7852&rft.eissn=1476-5608&rft_id=info:doi/10.1038/s41391-024-00797-0&rft_dat=%3Cproquest_cross%3E2933462676%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c298t-98b7240abd7bcbc9ae15516dc137f7289c44e1f81e327b1c588c869e3c9429733%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2933462676&rft_id=info:pmid/38418892&rfr_iscdi=true